Key result
Plasma multiomics model strongly predicts future stroke in hypertensive patients with ~0.97 AUC.
Why the study?
The study aimed to investigate the correlation between plasma proteins and metabolites and future stroke occurrence, and to identify biomarkers predictive of stroke risk in hypertensive patients.
Can plasma multiomics profiling and machine learning models predict the occurrence of future strokes in hypertensive patients?
Case-Control (n=100)
Can plasma multiomics profiling and machine learning models predict the occurrence of future strokes in hypertensive patients?
Effect estimate: AUC 0.973 (95% CI 0.921-0.999)
A machine-learning model integrating plasma multiomics biomarkers accurately predicts future stroke risk in hypertensive patients.
May aid stroke risk stratification in hypertension; hypothesis-generating and requires prospective validation before clinical use.
We aimed to investigate the correlation between plasma proteins and metabolites and the occurrence of future strokes using mass spectrometry and bioinformatics as well as to identify other biomarkers that could predict stroke risk in hypertensive patients. In a nested case-control study, baseline plasma samples were collected from 50 hypertensive subjects who developed stroke and 50 gender-, age- and body mass index-matched controls. Plasma untargeted metabolomics and data independent acquisition-based proteomics analysis were performed in hypertensive patients, and 19 metabolites and 111 proteins were found to be differentially expressed. Integrative analyses revealed that molecular changes in plasma indicated dysregulation of protein digestion and absorption, salivary secretion, and regulation of actin cytoskeleton, along with significant metabolic suppression. C4BPA, Caprolactam, Col15A1, and HBB were identified as predictors of stroke occurrence, and the Support Vector Machines (SVM) model was determined to be the optimal predictive model by integrating six machine-learning classification models. The SVM model showed strong performance in both the internal validation set (area under the curve [AUC]: 0.977, 95% confidence interval [CI]: 0.941-1.000) and the external independent validation set (AUC: 0.973, 95% CI: 0.921-0.999).
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2024) conducted a case-control in Hypertension and Stroke (n=100). Support Vector Machines (SVM) predictive model based on multiomics profiling was evaluated on Prediction of stroke occurrence (AUC 0.973, 95% CI 0.921-0.999). A Support Vector Machines model integrating plasma multiomics biomarkers (C4BPA, Caprolactam, Col15A1, HBB) strongly predicted future stroke in hypertensive patients (external validation AUC 0.973).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: